Aveo Pharmaceuticals Inc
NASDAQ:AVEO
Intrinsic Value
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of AVEO.
Aveo Pharmaceuticals Inc's market capitalization is 519.3m USD.
AVEO stock price is 15 USD.
AVEO.
AVEO. Open DCF Valuation
AVEO. Open Relative Valuation
AVEO.
AVEO's D/E (Debt to Equity) is very low and is equal to 0.94.
AVEO's long-term assets (101m USD) exceed its long-term liabilties (72m USD).
AVEO's Revenue has grown by an exceptional 269% over the past 12 months.
AVEO's ROE (Return on Equity) has significantly increased in the last 3 years from -124% to -73%, and is approaching profitability.
AVEO's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -2 489% to -169%, and is approaching profitability.
AVEO has positive Gross Profit for the last twelve months.
AVEO has negative Operating Income for the last twelve months.
AVEO has negative Net Income for the last twelve months.
AVEO's ROE (Return on Equity) for the past 12 months is negative and is equal to -73%.
AVEO's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -169%.
AVEO's short-term assets (101m USD) exceed its short-term liabilties (42m USD).
AVEO's Revenue is forecast to grow at a rate of 77% per year over the next 3 years.
AVEO has negative Net Debt. This means that the company has more cash and short-term investments (77m USD) than debt (27m USD).
AVEO has negative Free Cash Flow for the last twelve months.
AVEO has negative three-year average ROE (Return on Equity): -100%. The company is not efficient at transforming stockholders' equity into net income.
AVEO has negative three-year average ROIC (Return on Invested Capital): -974%. The company is not efficient at using invested capital to generate operating income.
AVEO's Altman Z-Score is very low and is equal to -7.36.
AVEO doesn't generate enough operating income (-24m USD) to safely cover interest payments on its debt (4m USD).
Fundamental Analysis
Aveo Pharmaceuticals Inc
Balance Sheet Decomposition
Aveo Pharmaceuticals Inc
| Current Assets | 100.7m |
| Cash & Short-Term Investments | 77.4m |
| Receivables | 19.8m |
| Other Current Assets | 3.6m |
| Non-Current Assets | 502k |
| PP&E | 257k |
| Other Non-Current Assets | 245k |
| Current Liabilities | 42.4m |
| Accounts Payable | 5m |
| Accrued Liabilities | 25.9m |
| Other Current Liabilities | 11.5m |
| Non-Current Liabilities | 30m |
| Long-Term Debt | 27.2m |
| Other Non-Current Liabilities | 2.8m |
Earnings Waterfall
Aveo Pharmaceuticals Inc
|
Revenue
|
94.3m
USD
|
|
Cost of Revenue
|
-11.5m
USD
|
|
Gross Profit
|
82.8m
USD
|
|
Operating Expenses
|
-107.3m
USD
|
|
Operating Income
|
-24.5m
USD
|
|
Other Expenses
|
-4.5m
USD
|
|
Net Income
|
-29m
USD
|
Free Cash Flow Analysis
Aveo Pharmaceuticals Inc
What is Free Cash Flow?
AVEO Profitability Score
Profitability Due Diligence
Aveo Pharmaceuticals Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
Score
Aveo Pharmaceuticals Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
AVEO Solvency Score
Solvency Due Diligence
Aveo Pharmaceuticals Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Score
Aveo Pharmaceuticals Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AVEO Price Targets Summary
Aveo Pharmaceuticals Inc
Ownership
AVEO Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
AVEO Price
Aveo Pharmaceuticals Inc
| Average Annual Return | -16.75% |
| Standard Deviation of Annual Returns | 14.36% |
| Max Drawdown | -79% |
| Market Capitalization | 519.3m USD |
| Shares Outstanding | 34 763 100 |
| Percentage of Shares Shorted | 2.36% |
AVEO News
Last Important Events
Aveo Pharmaceuticals Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Aveo Pharmaceuticals Inc
Company Profile
Aveo Pharmaceuticals Inc
Country
Industry
Market Cap
Dividend Yield
Description
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. The company is headquartered in Boston, Massachusetts and currently employs 114 full-time employees. The company went IPO on 2010-03-12. The firm is focused on delivering medicines for patients with cancer. The Company’s commercial product include FOTIVDA (tivozanib), which is an oral, vascular endothelial growth factor receptor (VEGFR) and tyrosine kinase inhibitor (TKI). The firm markets FOTIVDA (tivozanib) in the United States for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. The company also develops FOTIVDA in immuno-oncology combinations in refractory RCC and other indications and has several other investigational programs in clinical development. The Company’s pipeline of product candidates includes ficlatuzumab, AV-380, AV-203 and AV-353. Its ficlatuzumab is a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor (HGF).
You don't have any saved screeners yet
